Oxford Biomedica, a gene and cell therapy company, said on Monday its loss before tax from continuing operations for the full year widened to £188.53 million ($236 million) from a £45.98 million loss in the previous year, primarily due to decline in revenue. Net loss was £157.49 million compared with a loss of £39.16 million last year. Revenue for the year decreased 36% to £89.54 million from £139.99 million a year ago, impacted by the non-recurrence of vaccine manufacturing revenues. Looking ahead, the British company has reaffirmed its fiscal 2024 outlook. It still sees revenue for 2024 to b…